de Jonge M, van Boxtel A G, Soliman Hamad M A, Mokhles M M, Bramer S, Osnabrugge R L J, van Straten A H M, Berreklouw E
Department of Cardiothoracic Surgery, Catharina Hospital, Eindhoven, The Netherlands.
Department of Cardiothoracic Surgery, Catharina Hospital, Eindhoven, The Netherlands
Perfusion. 2015 Apr;30(3):243-9. doi: 10.1177/0267659114540023. Epub 2014 Jun 26.
This study analyzes the efficacy in myocardial protection of two types of cardioplegia solutions, namely, blood and crystalloid cardioplegia, both given intermittently in patients undergoing coronary artery bypass grafting (CABG).
Adult patients undergoing primary isolated coronary artery bypass grafting between January 1998 and January 2011 with cardiopulmonary bypass, using either blood or crystalloid cardioplegia, were identified in our database. Propensity score matching was performed to create comparable patient groups. Multivariate logistic regression analysis was performed to identify independent risk factors for perioperative myocardial damage. The primary endpoint of the study was the maximum creatine kinase-MB (CK-MB) value within 5 days postoperatively with a cut-off point of 100 U/L. Early mortality and perioperative low cardiac output syndrome in both groups were compared.
The study included 7138 CABG patients: 3369 patients using crystalloid cardioplegia and 3769 using blood cardioplegia. After propensity score matching, 2585 patients per study group remained for the analysis. Wilcoxon signed-rank test revealed significantly higher CK-MB levels in patients operated with the use of blood cardioplegia. Multivariate regression analysis identified blood cardioplegia as an independent risk factor for elevated CK-MB levels. However, it was associated with lower aspartate aminotransferase (AST) levels. The type of cardioplegia had no influence on early mortality, postoperative low cardiac output syndrome or intensive care unit stay.
Blood cardioplegia was identified as an independent risk factor for elevated levels of CK-MB after CABG, but was associated with lower AST levels. The authors conclude that the type of cardioplegia had no significant influence on clinical outcome.
本研究分析两种心脏停搏液(即含血心脏停搏液和晶体心脏停搏液)在冠状动脉旁路移植术(CABG)患者中间歇给药时对心肌保护的效果。
在我们的数据库中识别出1998年1月至2011年1月期间接受初次单纯冠状动脉旁路移植术并行体外循环的成年患者,这些患者使用含血或晶体心脏停搏液。进行倾向评分匹配以创建可比的患者组。进行多因素逻辑回归分析以确定围手术期心肌损伤的独立危险因素。该研究的主要终点是术后5天内肌酸激酶同工酶(CK-MB)的最高值,临界值为100 U/L。比较两组的早期死亡率和围手术期低心排血量综合征。
该研究纳入7138例CABG患者:3369例使用晶体心脏停搏液,3769例使用含血心脏停搏液。倾向评分匹配后,每个研究组仍有2585例患者用于分析。Wilcoxon符号秩检验显示使用含血心脏停搏液进行手术的患者CK-MB水平显著更高。多因素回归分析确定含血心脏停搏液是CK-MB水平升高的独立危险因素。然而,它与较低的天冬氨酸转氨酶(AST)水平相关。心脏停搏液的类型对早期死亡率、术后低心排血量综合征或重症监护病房住院时间没有影响。
含血心脏停搏液被确定为CABG后CK-MB水平升高的独立危险因素,但与较低的AST水平相关。作者得出结论,心脏停搏液的类型对临床结局没有显著影响。